Books on obesity science and the drug race: a 2026 reading list

Prepared by: Research Desk. Sources are linked for verification.

Trial readouts and FDA decisions arrive faster than most readers can absorb them. Books can't keep up with that news, but they explain the background that makes the news readable. They cover how appetite is regulated, why body weight resists change, how a molecule becomes a medicine, and how to tell a strong trial result from a weak one. This list groups thirteen books by theme. Each entry says what the book covers, how demanding it is and which reader it suits.

Why the obesity-drug story is worth reading up on in 2026

The field has changed quickly. According to a May 2026 industry pipeline summary, two oral GLP-1 drugs had been approved in the U.S. for weight management: orforglipron, a small molecule, and higher-dose oral semaglutide [1]. The same summary listed an FDA decision on cagrilintide plus semaglutide as expected in December 2026, and an FDA decision on retatrutide as a 2027 event [1].

The published trial numbers explain much of the attention:

• Retatrutide (TRIUMPH-1). This trial followed 2,339 adults with obesity for 80 weeks. Mean weight change ranged from −17.6% to −25.0% across the retatrutide groups, versus −3.9% with placebo [2]. Retatrutide is investigational.

• Orforglipron (ATTAIN-2). This 72-week trial enrolled 1,613 adults with obesity or overweight and type 2 diabetes. Mean weight change under the treatment-regimen estimand ranged from −5.1% to −9.6% across the orforglipron groups, versus −2.5% with placebo [3].

• Cagrilintide plus semaglutide (REDEFINE 5). In a 68-week trial in adults in Japan and Taiwan, the combination produced −18.4% mean weight change, versus −11.9% with semaglutide alone [4].

These figures come from different populations, trial lengths and comparators. They are not directly comparable, which is one reason a grounding in trial design is useful.

There is also a regulatory side: investigational compounds are being sold outside the legal supply chain. Our regulatory explainer sets out what the FDA has said about that parallel market.

Science, commercial stakes and regulation all move together in this story. No single book covers all three, so the list below is built as a set. None of these books includes 2026 trial data. For that, see our current pipeline status tracker.

How we chose these books

Every title had to meet these criteria:

• Explains, doesn't promise. The book explains mechanisms, systems or history. It does not offer a plan with promised results.

• Traceable sourcing. The book has endnotes or references that lead back to studies and records.

• Credible author. The author is a working scientist, an academic or an investigative writer with a published record on the subject.

• Still useful. Older books stay on the list only if their core argument still holds. We flag where the science or market has moved on.

• A spread of reading levels. The list runs from narrative non-fiction to textbooks.

When choosing between titles, check the edition date against the pipeline timeline, whether the notes section is substantial, and whether the format suits the purpose. Editions and subtitles change, so confirm the current edition at the retailer before buying. Libraries carry most of these titles, which makes it easy to sample one first. Nothing on this list makes, or should be read as making, any claim about health effects.

Appetite, hormones and metabolism: the science shelf

The Hungry Brain: Outsmarting the Instincts That Make Us Overeat, by Stephan Guyenet (2017). Guyenet is a neuroscientist. He explains how the brain regulates appetite and body fat, including the role of leptin and the brain's reward systems, and why the modern food environment pulls against those systems. Reading level: introductory to intermediate. Suits: general readers who want the neuroscience behind why appetite-targeting drugs became a research focus.

Burn, by Herman Pontzer (2021). An evolutionary anthropologist reports on energy-expenditure research, including fieldwork with the Hadza in Tanzania. He argues that total daily energy expenditure is more constrained than simple calorie arithmetic suggests. Reading level: introductory. Suits: readers who want to understand why body weight is regulated and resistant to change, explained through measurement studies.

The Secret Life of Fat, by Sylvia Tara (2016). A biochemist describes fat tissue as an active organ that releases hormones, and tells the discovery stories behind leptin and related research. Reading level: introductory. Suits: newcomers to endocrinology and anyone who wants the history of how fat came to be studied as signalling tissue.

Ultra-Processed People, by Chris van Tulleken (2023). This book examines industrially processed food, how it is designed and marketed, and the research on how it affects eating. It is also a book about corporate incentives. Reading level: introductory. Suits: readers interested in the food-environment side of obesity research.

Drug discovery and the pharmaceutical industry

The Drug Hunters: The Improbable Quest to Discover New Medicines, by Donald R. Kirsch and Ogi Ogas (2017). A veteran industry researcher and a science writer trace drug discovery from plant extracts to synthetic chemistry and biologics, stressing how much depends on chance and failure. Reading level: introductory. Suits: investors and general readers who want a realistic sense of attrition before reading pipeline tables.

The Billion-Dollar Molecule, by Barry Werth (1994). This book follows the early years of Vertex Pharmaceuticals as it tried to design drugs from protein structures. The specific science is dated; its portrait of financing, competition and scientific rivalry is not. Reading level: intermediate. Suits: investors and anyone curious about how drug companies are built and funded.

The Truth About the Drug Companies, by Marcia Angell (2004). A former editor-in-chief of the New England Journal of Medicine critiques industry spending, pricing and the focus on "me-too" drugs. The market data are two decades old, but her questions about pricing and incremental innovation recur in today's debates. Reading level: introductory to intermediate. Suits: readers who want a sceptical counterweight to company presentations.

Magic Pill, by Johann Hari (2024). A journalist's first-person account of the new weight-loss injectables, mixing interviews with researchers and critics and weighing reported upsides against risks and social questions. Read it as a narrative rather than a reference: its personal experience is anecdote, and its trial figures predate the 2026 data above. Reading level: introductory. Suits: general readers who want the cultural debate alongside the science.

Regulation, trials and reading evidence

Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, by Daniel Carpenter (2010). An academic history of how the FDA built its authority, including approval standards and the phased clinical trial system. Reading level: advanced. Suits: policy readers, students and investors who want to understand why the agency behaves as it does.

Drugs: From Discovery to Approval, by Rick Ng. A textbook overview of each development stage: target selection, preclinical work, clinical phases and regulatory submissions. Reading level: intermediate to advanced. Suits: readers who want the vocabulary behind terms like "phase 3" and "marketing application".

Bad Pharma, by Ben Goldacre (2012). Goldacre examines missing trial data, publication bias, weak comparators and gaps in regulation. Some reforms he called for have since moved forward, but his checklist remains a sharp lens for reading any press release. Reading level: intermediate. Suits: anyone who reads trial headlines, investors especially.

How to Read a Paper, by Trisha Greenhalgh (first published 1997, with later editions). A standard text on appraising study types, statistics and bias. Reading level: intermediate. Suits: readers who want to check primary papers like the ones cited on this site.

Statistics Done Wrong, by Alex Reinhart (2015). A short, plain-language tour of common statistical errors: p-value misreadings, underpowered studies and multiple comparisons. Reading level: introductory to intermediate. Suits: non-statisticians who want to spot weak analyses quickly.

Pair these with the estimand explanation in our pipeline guide, which shows why one trial can report two different headline figures.

What we leave off the list

We exclude diet books that promise results, titles that encourage use of investigational or unapproved substances, and quick-turnaround cash-ins built around trademarked drug names, which tend to be thin on sourcing. We describe books only by what they cover, never by any effect they might have.

Quick comparison table: topic, reading level, best suited to

Tools and further reading

To build a short shelf, pick one title from each theme: one on the science, one on the industry and one on evidence. Readers new to the subject could begin with the introductory titles. Investors could begin with the industry and evidence shelves.

Before buying, compare edition dates, check that the book has full endnotes, and choose the format that matches how the book will be used. Reference texts are easier to search as ebooks, while narratives work well as audiobooks.

Any paid link on this site is labelled next to the link. Our about page explains how paid links are labelled and how the site is funded.

Last updated: 18 October 2026.

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.